These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

370 related items for PubMed ID: 29429477

  • 1. [Novel antidiabetic drugs and cardiovascular complications].
    Pareek M, Mortensen MB, Løfgren B, Nielsen ML, Olsen MH, Andersen NH.
    Ugeskr Laeger; 2018 Feb 05; 180(6):. PubMed ID: 29429477
    [Abstract] [Full Text] [Related]

  • 2. [Not Available].
    Toft E, Rydén M.
    Lakartidningen; 2018 Feb 20; 115():. PubMed ID: 29461566
    [Abstract] [Full Text] [Related]

  • 3. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.
    Alfayez OM, Al Yami MS, Alshibani M, Fallatah SB, Al Khushaym NM, Alsheikh R, Alkhatib N.
    Prim Care Diabetes; 2019 Jun 20; 13(3):204-211. PubMed ID: 30713085
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.
    Karasik A, Lanzinger S, Chia-Hui Tan E, Yabe D, Kim DJ, Sheu WH, Melzer-Cohen C, Holl RW, Ha KH, Khunti K, Zaccardi F, Subramanian A, Nirantharakumar K, Nyström T, Niskanen L, Linnemann Jensen M, Hoti F, Klement R, Déruaz-Luyet A, Kyaw MH, Koeneman L, Vistisen D, Carstensen B, Halvorsen S, Langslet G, Fazeli Farsani S, Patorno E, Núñez J, EMPRISE Europe and Asia Study Group.
    Diabetes Metab; 2023 Mar 20; 49(2):101418. PubMed ID: 36608816
    [Abstract] [Full Text] [Related]

  • 6. Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?
    Packer M.
    Am J Med; 2018 May 20; 131(5):461-463. PubMed ID: 29309741
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Contrasting effects on the risk of macrovascular and microvascular events of antihyperglycemic drugs that enhance sodium excretion and lower blood pressure.
    Packer M.
    Diabet Med; 2018 Jun 20; 35(6):707-713. PubMed ID: 29532519
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and mild/moderate chronic kidney disease.
    Rhee JJ, Han J, Montez-Rath ME, Chertow GM.
    Diabetes Obes Metab; 2024 Apr 20; 26(4):1273-1281. PubMed ID: 38186297
    [Abstract] [Full Text] [Related]

  • 12. Review of cardiovascular outcomes trials of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.
    North EJ, Newman JD.
    Curr Opin Cardiol; 2019 Nov 20; 34(6):687-692. PubMed ID: 31436559
    [Abstract] [Full Text] [Related]

  • 13. Cardiovascular effects of antidiabetic drugs.
    Sørensen AM, Christensen MB.
    Drugs Today (Barc); 2018 Sep 20; 54(9):547-559. PubMed ID: 30303495
    [Abstract] [Full Text] [Related]

  • 14. Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis.
    Kramer CK, Ye C, Campbell S, Retnakaran R.
    JACC Heart Fail; 2018 Oct 20; 6(10):823-830. PubMed ID: 30196071
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Novel antidiabetic drugs and cardiovascular risk: Primum non nocere.
    Bonadonna RC, Borghi C, Consoli A, Volpe M.
    Nutr Metab Cardiovasc Dis; 2016 Sep 20; 26(9):759-66. PubMed ID: 27373139
    [Abstract] [Full Text] [Related]

  • 17. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S, Jolly G, Horblitt A, Sanaani A, Aronow WS.
    Postgrad Med; 2017 Nov 20; 129(8):811-821. PubMed ID: 28749197
    [Abstract] [Full Text] [Related]

  • 18. Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure.
    Sinha B, Ghosal S.
    Diabetes Res Clin Pract; 2019 Apr 20; 150():8-16. PubMed ID: 30794833
    [Abstract] [Full Text] [Related]

  • 19. Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.
    Niessner A, Tamargo J, Koller L, Saely CH, Schmidt TA, Savarese G, Wassmann S, Rosano G, Ceconi C, Torp-Pedersen C, Kaski JC, Kjeldsen KP, Agewall S, Walther T, Drexel H, Lewis BS.
    Eur Heart J; 2018 Jun 21; 39(24):2274-2281. PubMed ID: 29126266
    [No Abstract] [Full Text] [Related]

  • 20. Glucose lowering and the kidney: are all drug classes equal?
    Wong MG, Jardine M, Perkovic V.
    Lancet Diabetes Endocrinol; 2018 Nov 21; 6(11):835-837. PubMed ID: 30292590
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.